Published on : Sep 04, 2017
Albany, New York, September 4, 2017: A new study by Market Research Hub (MRH) provides a detailed analysis on the prospects of Upadacitinib drug, which has been recently unveiled by AbbVie for treating late-stage rheumatoid arthritis. In the report, titled “Upadacitinib-Launch Insights, 2017” comprehensive information and projections have been provided on the expected launch of Upadacitinib. The report highlights all the indications for which the drug can be currently used as well as offers a wide landscape for the major indications. The report also offers insights on post launch market positioning, projected sales of the drugs and patent policies.
After AbbVie reported a strong late-stage success of upadacitinib (ABT-494) in patients suffering from severe and moderate rheumatoid. The company is hopping to receive a green signal from regulatory authorities for launching the experimental anti-inflammatory drug. The drug is expected to perform exceptionally in the market if approved. This is expected to bring good news for Abbvie’s investors. The biotech company has one of the strongest R&D pipeline in the biopharmaceutical division. Abbvie is expected to remain leading drug manufacturer for autoimmune diseases thanks to late-stage drugs such as Risankizumab and Upadacitinib. Few other encouraging experimental cancer medicines in the company’s pipeline include Veliparib and Rova-T. In addition, Elagolix could further provide an impetus to put Abbvie in strong position in treating uterine and endometriosis.
MRH’ report projects that major growth drivers for Upadacitinib include increasing occurrence of rheumatoid arthritis, increasing approvals of biosimilars and early diagnosis and treatment. The report also gives information on the current market positioning for the approaching Upadacitinib launch and offer key insights on how Upadacitinib will gain traction in the market and within its respective class. The report offer thorough information on the trial phases that are either being cleared or have been cleared. Insightful and detailed information regarding the clinical trials is obtained by evaluating the trial outcomes. The exhaustive analysis provided in the report will help the reader to understand how the Upadacitinib’s launch is compared with other contenders (in pipeline and in market). The comparison is based on analyzing data form various important clinical trials of the product. A direct comparison with other similar marketed products has been drawn if conceivable. In addition, the report is compiled using information and data and sourced from secondary and primary research, in-house analysis by industry experts, and proprietary databases.
Secondary data and information have been collected from using various online and offline sources, which include, news websites, search engines, trade journals, government websites, trade associations, white papers, magazines, books, industry associations, and industry portals. The report also provides a detailed product description including its molecule type, mechanism of action and chemical properties. The reader will also get information on clinical and non-clinical studies for all the indications. Other vital insights on competitors along with patent expiry results are also available in the report. The report also projects overall increase in demand for Upadacitinib as well as its market positioning analysis and class share growth in the forthcoming years.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1309675
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org